The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Open accessAbstract
Background: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure ( HF ) and cardiomyopathy ( CM ). However, clinical trials may underestimate HF / CM risk because they enroll younger subjects with fewer cardiac risk factors. We sought to develop a clinical risk score that identifies older women with breast cancer who are at higher risk of HF or CM after trastuzumab. Methods and Results: Using the Surveillance, Epidemiology and End Results ( SEER )‐Medicare database, we identified women with breast cancer who received adjuvant trastuzumab. Using a split‐sample design, we used a proportional hazards model to identify candidate predictors of HF / CM in a derivation cohort. A risk score was constructed using regression coefficients, and HF / CM rates were calculated in the validation cohort. The sample consisted of 1664 older women (mean age 73.6 years) with 3‐year HF / CM rate of 19.1%. A risk score consisting of age, adjuvant chemotherapy, coronary artery disease, atrial fibrillation or flutter, diabetes mellitus, hypertension, and renal failure was able to classify HF / CM risk into low (0 to 3 points), medium (4 to 5 points), and high (≥6 points) risk strata with 3‐year rates of 16.2%, 26.0%, and 39.5%, respectively. Conclusions: A 7‐factor risk score was able to stratify 3‐year risk of HF / CM after trastuzumab between the lowest and highest risk groups by more than 2‐fold in a Medicare population. These findings will inform future research aimed at further developing a clinical risk score for HF / CM for breast cancer patients of all ages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Comorbidity measures for use with administrative data.
Elixhauser, A., Steiner, C., Harris, D. R., & Coffey, R. M. (1998) · Medical Care · doi:10.1097/00005650-199801000-00004 · Cited by 9,921
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Greenland, P. (2004) · JAMA · doi:10.1001/jama.291.2.210 · Cited by 1,829
Presentation of multivariate data for clinical use: The Framingham Study risk score functions
Sullivan, L. M., Massaro, J. M., & D'Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1742 · Cited by 1,753
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
(1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.6.1071 · Cited by 1,137
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Sapisochin, E. (1962) · PubMed · Cited by 903
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 814
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · Medical Care · doi:10.1097/00005650-200208001-00002 · Cited by 772
Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors
Birman-Deych, E., Waterman, A. D., Yan, Y., Nilasena, D. S., Radford, M. J., & Gage, B. F. (2005) · Medical Care · doi:10.1097/01.mlr.0000160417.39497.a9 · Cited by 719
The National Cholesterol Education Program
Cleeman, J. I. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30638-3 · Cited by 710
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales-Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.072 · Cited by 632
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
Romond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Fallah-Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 484
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
Utility of the SEER-Medicare Data to Identify Chemotherapy Use
Warren, J. L., Harlan, L. C., Fahey, A., Virnig, B. A., Freeman, J. L., Klabunde, C. N., Cooper, G. S., & Knopf, K. B. (2002) · Medical Care · doi:10.1097/00005650-200208001-00008 · Cited by 404
Assessing Comorbidity Using Claims Data: An Overview
Klabunde, C. N., Warren, J. L., & Legler, J. M. (2002) · Medical Care · doi:10.1097/00005650-200208001-00004 · Cited by 382
Lee, D. S., Donovan, L., Austin, P. C., Gong, Y., Liu, P. P., Rouleau, J. L., & Tu, J. V. (2005) · Medical Care · doi:10.1097/00005650-200502000-00012 · Cited by 358
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Chen, J., Long, J. B., Hurria, A., Owusu, C., Steingart, R. M., & Gross, C. P. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.068 · Cited by 352
Self-citationRosamond, W. D., Chang, P. P., Baggett, C., Johnson, A., Bertoni, A. G., Shahar, E., Deswal, A., Heiss, G., & Chambless, L. E. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.111.963199 · Cited by 349
C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study
Wilson, P. W. F., Pencina, M., Jacques, P., Selhub, J., D'Agostino, R., & O'Donnell, C. J. (2008) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.831198 · Cited by 299
Hare, J. L., Brown, J. K., Leano, R., Jenkins, C., Woodward, N., & Marwick, T. H. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.05.031 · Cited by 230
Goff, D. C., Pandey, D. K., Chan, F. A., Ortiz, C., & Nichaman, M. Z. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.2.197 · Cited by 222
Jones, A. L., Barlow, M., Barrett-Lee, P. J., Canney, P. A., Gilmour, I. M., Robb, S. D., Plummer, C. J., Wardley, A. M., & Verrill, M. W. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604909 · Cited by 213
Sandri, M. T., Cardinale, D. M., Zorzino, L., Passerini, R., Lentati, P., Martinoni, A., Martinelli, G., & Cipolla, C. M. (2003) · Clinical Chemistry · doi:10.1373/49.2.248 · Cited by 123
Reliability in Adolescent Reporting of Clinician Counseling, Health Care Use, and Health Behaviors
Santelli, J. S., Klein, J. D., Graff, C. A., Allan, M. J., & Elster, A. B. (2002) · Medical Care · doi:10.1097/00005650-200201000-00005 · Cited by 104
Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy
Jeyakumar, A. S., DiPenta, J., Snow, S. L., Rayson, D., Thompson, K., Theriault, C., & Younis, T. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.07.006 · Cited by 27
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Metadata
- Authors
- Ezaz, G., Long, J. B., Gross, C. P., & Chen, J.
- Venue
- Journal of the American Heart Association
- Published
- 2014-01-27
- Volume
- 3
- Issue
- 1
- Pages
- e000472-e000472
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2111350156
- Cited by
- 276
- References
- 40
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.